Related Experiment Video
Updated: Jan 12, 2026
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Pharmacotherapy development and trends in lipidology: An expert discussion
Michael H Davidson1, Kevin C Maki2
1NewAmsterdam Pharma, Naarden, The Netherlands (Dr. Davidson); Lipid Clinic, Pritzker School of Medicine, University of Chicago, Chicago, IL, USA (Dr. Davidson).
Insights
Atherosclerotic cardiovascular diseases (ASCVD) are a major global health concern. Experts discuss challenges and trends in developing new lipid-lowering therapies and emphasize early intervention for ASCVD risk reduction.
Area of Science:
- Cardiology and Lipidology
- Pharmacology and Drug Development
Background:
- Cardiovascular diseases (CVDs), particularly atherosclerotic cardiovascular diseases (ASCVD), are primary drivers of mortality and morbidity worldwide.
- Elevated atherogenic lipoproteins significantly contribute to ASCVD development, making their management crucial for risk reduction.
Purpose of the Study:
- To discuss challenges and emerging trends in the development of novel lipid-lowering pharmacotherapies.
- To highlight the importance of early intervention and multifactorial risk management in reducing ASCVD burden.
Main Methods:
- Expert discussion and consensus on current challenges in therapeutic development.
- Review of current trends in lipidology and potential opportunities for new drug targets.
Main Results:
- Identification of key challenges in developing new therapeutics for lipid disorders.
- Exploration of emerging trends in lipidology that may inform future pharmacotherapies.
Conclusions:
- Novel therapeutic targets and strategies are needed to combat ASCVD.
- Early and comprehensive management of cardiovascular risk factors is essential for mitigating ASCVD morbidity and mortality.
Abstract:
Cardiovascular diseases are leading causes of morbidity and mortality in the United States and globally. Atherosclerotic cardiovascular diseases (ASCVD), such as coronary heart disease and cerebrovascular disease, cause a majority of cardiovascular disease deaths. The treatment of elevated atherogenic lipoproteins is a key aspect of efforts to reduce the risk of ASCVD. The identification of novel targets that may influence ASCVD risk has contributed to efforts to develop new therapeutics. Dr. Michael H. Davidson and Dr. Kevin C. Maki, 2 experts in the field of lipidology and the development of novel pharmaceuticals, share a conversation in which they discuss the challenges to consider when developing new therapeutics and the trends in the field of lipidology that may create opportunities for new pharmacotherapies. Dr. Davidson and Dr. Maki also discuss the importance of implementing treatment early in life and of addressing multiple risk factors to reduce the risk of ASCVD and the associated burdens of morbidity and mortality.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Atherosclerosis III: Management
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
01:26Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:24Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug